- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02018731
L-citrulline and Metformin in Becker's Muscular Dystrophy
Pilot Study to Assess the Efficacy of L-Citrulline and Metformin in Adults With Becker's Muscular Dystrophy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, not-randomized open study. The study medication consists of L-citrulline and metformin administered orally; 5g citrulline and 500mg metformin tablets will be given 3 times daily.
Half of the patients will be treated with metformin during the first 6 weeks of the study. The other patients will receive initially L-citrulline for 6 weeks, before all patients will be treated with the combination therapy (metformin and L-citrulline) for another 6 week period.
The study lasts 12 weeks and includes the screening visit and 3 further visits at baseline, week 6 and week 12.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
BS
-
Basel, BS, Switzerland, 4031
- University Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Molecular or immunohistochemical diagnosis of BMD
- ambulant at the time point of screening
Exclusion Criteria:
- Participation in another therapeutic BMD study within the last 3 months
- Use of L-Arginine, L-Citrulline or Metformin within the last 3 months
- Other chronic disease or relevant limitation of renal, liver, heart function according to discretion of investigator
- known hypersensitivity to L-citrulline or metformin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metformin and Metformin & L-Citrulline
1500 mg/d metformin for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
|
|
Experimental: L-Citrulline and Metformin & L-Citrulline
15 g/d L-citrulline for 6 weeks, followed by 1500 mg/d metformin and 15 g/d L-citrulline for 6 further weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mean change of motor function measure (MFM) D1 subscore after 6 and 12 weeks
Time Frame: week 6 and week 12
|
week 6 and week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MFM total score and six minute walking distance (6MWD)
Time Frame: week 6 and week 12
|
week 6 and week 12
|
Change of muscle fat content (MFC) (assessed by MRI)
Time Frame: week 6 and week 12
|
week 6 and week 12
|
Change of muscle metabolism (assessed by dual energy x-ray absorptiometry (DEXA) and indirect calorimetry)
Time Frame: week 6 and week 12
|
week 6 and week 12
|
Change of laboratory parameters (oxidative and nitrosative stress)
Time Frame: week 6 and week 12
|
week 6 and week 12
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dirk Fischer, MD, University Children's Hospital Basel
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BMD01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Becker's Muscular Dystrophy (BMD)
-
Massachusetts General HospitalCompletedDuchenne Muscular Dystrophy | Dystrophinopathy | Becker's Muscular DystrophyUnited States
-
University of BernUniversity Hospital Inselspital, Berne; University of Lausanne Hospitals; University... and other collaboratorsRecruitingCongenital Muscular Dystrophy | SMA | DMD | BMD | IMDSwitzerland
-
Avidity Biosciences, Inc.RecruitingPhase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) (FORTITUDE)Muscular Dystrophies | Muscular Dystrophy, Facioscapulohumeral | FSHD | Facio-Scapulo-Humeral Dystrophy | FMD | Facioscapulohumeral Muscular Dystrophy 1 | FSHD2 | FSHD1 | FMD2 | Fascioscapulohumeral Muscular Dystrophy | Fascioscapulohumeral Muscular Dystrophy Type 1 | Fascioscapulohumeral Muscular Dystrophy... and other conditionsUnited States, United Kingdom, Canada
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedBecker Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy | Limb-Girdle Muscular DystrophyUnited States
-
Massachusetts General HospitalUniversity of Pittsburgh; Boston Children's Hospital; Brigham and Women's Hospital and other collaboratorsRecruitingDuchenne Muscular Dystrophy | Becker Muscular Dystrophy | Myotonic Dystrophy | Facioscapulohumeral Muscular DystrophyUnited States
-
University of North Carolina, Chapel HillNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedMuscular Dystrophies | Duchenne Muscular Dystrophy | Becker Muscular Dystrophy | Limb-Girdle Muscular DystrophyUnited States
-
Boston Children's HospitalNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingLimb-girdle Muscular Dystrophy | Neuromuscular; Disorder, Hereditary | Duchenne/Becker Muscular DystrophyUnited States
-
Rigshospitalet, DenmarkCompletedBecker Muscular Dystrophy | Limb-Girdle Muscular Dystrophy Type 2IDenmark
-
Laurent ServaisSYSNAVRecruitingDuchenne Muscular Dystrophy | Fascioscapulohumeral Muscular DystrophyBelgium
-
Virginia Commonwealth UniversityEdgewise Therapeutics, Inc.RecruitingMuscular Dystrophies | Becker Muscular Dystrophy | Muscular Dystrophy in Children | Muscular Dystrophy, BeckerUnited States, United Kingdom
Clinical Trials on Metformin and Metformin & L-Citrulline
-
University Hospital, Basel, SwitzerlandCompletedDuchenne's Muscular Dystrophy (DMD)Switzerland
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Asklepion Pharmaceuticals, LLCVanderbilt UniversityCompletedHypertension, Pulmonary | Heart Defects, CongenitalUnited States
-
University of PittsburghCompleted
-
Asklepion Pharmaceuticals, LLCCompletedAtrial Septal Defect | Atrioventricular Septal Defect | Ventricular Septal DefectUnited States
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Florida State UniversityCompletedHypertensionUnited States
-
Juliano CasonattoUnknown
-
University of Colorado, DenverCompleted
-
University of JordanUnknownType 2 Diabetes MellitusJordan